Tested treatment plan for locally advanced rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 study looks at a modified “sandwich” treatment sequence for people with locally advanced rectal cancer—aiming to control the cancer before and after surgery. It may help you if you’re eligible and can follow the study’s treatment and safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed rectal adenocarcinoma (a specific type of rectal cancer).
- Your cancer stage fits T3–T4 or T any with lymph node spread, and your team expects it can be fully removed with surgery (R0 resection).
- There is no spread to distant organs (no metastasis).
- You do not currently have an intestinal blockage; if you had one, it must be relieved after a proximal colostomy.
- You are between 18 and 75 years old.
- You have not had any prior radiation, surgery, or chemotherapy for this cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination for locally advanced rectal cancer: adding a cholesterol-lowering drug plus an immunotherapy drug to the standard chemotherapy and radiation before surgery. The goal is to see if this combination shrinks tumors more effectively and improves outcomes.
This trial tests a combination of low-dose radiation, an immunotherapy drug called pucotenlimab, and chemotherapy for locally advanced rectal cancer that has not spread. The goal is to see if adding radiation helps shrink the tumor more effectively before surgery.
This trial compares a standard approach (chemotherapy and radiation before surgery) to a more intensive treatment (total neoadjuvant therapy plus radiation) for locally advanced rectal cancer. It aims to see if the stronger treatment helps remove the tumor and improves outcomes.
This trial tests whether adding an immunotherapy drug (dostarlimab) to standard chemotherapy after the usual chemoradiation helps treat locally advanced rectal cancer better than chemotherapy alone. Immunotherapy helps your immune system fight cancer cells, and may improve outcomes.
This trial tests a new combination for rectal cancer that hasn't spread far: a short course of radiation followed by two drugs (AK112 and CAPOX). The goal is to shrink the tumor before surgery and possibly avoid more aggressive treatments.
This trial tests whether adding two types of immunotherapy (cemiplimab with either fianlimab or REGN7075) to standard chemotherapy is safe and effective for people with locally advanced rectal cancer that has not been treated before. It may help shrink the tumor enough to allow surgery that preserves the ability to control bowel movements.
Hear when a new Advanced Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.